However, while combination of TMZ with STAT5 inhibition prolongs survival in EGFRvIII+ GBM, we calculated the equivalent dose of pimozide required to inhibit STAT5 in patient CNS tumors (0.8 mg/kg in humans) and found this to be above the safe maximum dose of no more than 0.2 mg/kg in adults, requiring alternative translational and clinical approaches to EGFRvIII-STAT5 signaling inhibition. Here, STAT5B is linked to central nervous system neoplasm.